Ranbaxy Laboratories Ltd on Monday announced the launch of Letrozole tablets 2.5 mg in the UK, Romania and France, on Day-1. Letrozole is an Antineoplastics, indicated for the treatment of breast cancer.
It is the bio-equivalent of Femara, the innovator product of Novartis, that has a market size of $58 million in UK (Source: IMS 2010), $95 million in France (Source: GERS May 2011) and $5.5 million in Romania (Source: Cegedim 2010).
Commenting on the Day-1 launch, Mr Debashis Dasgupta, Regional Director, Ranbaxy, Europe, said, “We are pleased to introduce Letrozole at the earliest available opportunity in the UK, Romania and France with a view to broadening access to medication. The product will be offered through pharmacies, retail and wholesale stores with immediate effect and will benefit the healthcare system in these EU markets.”
Ranbaxy's subsidiary companies, Ranbaxy (UK) Ltd, Terapia Ranbaxy and Ranbaxy Pharmacie Generiques will be marketing this product in UK, Romania and France respectively.